These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 39243430)

  • 1. Optimization of anti-TIM3 chimeric antigen receptor with CD8α spacer and TNFR-based costimulation for enhanced efficacy in AML therapy.
    Pe KCS; Jewmoung S; Rad SAH; Chantarat N; Chanswangphuwana C; Tashiro H; Suppipat K; Tawinwung S
    Biomed Pharmacother; 2024 Oct; 179():117388. PubMed ID: 39243430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
    Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
    Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
    Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
    Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inclusion of 4-1BB Costimulation Enhances Selectivity and Functionality of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells.
    Starr R; Aguilar B; Gumber D; Maker M; Huard S; Wang D; Chang WC; Brito A; Chiu V; Ostberg JR; Badie B; Forman SJ; Alizadeh D; Wang LD; Brown CE
    Cancer Res Commun; 2023 Jan; 3(1):66-79. PubMed ID: 36968221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors.
    Nishimura CD; Corrigan D; Zheng XY; Galbo PM; Wang S; Liu Y; Wei Y; Suo L; Cui W; Mercado N; Zheng D; Zhang CC; Zang X
    Sci Adv; 2024 May; 10(19):eadk1857. PubMed ID: 38718110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
    Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.
    Roselli E; Boucher JC; Li G; Kotani H; Spitler K; Reid K; Cervantes EV; Bulliard Y; Tu N; Lee SB; Yu B; Locke FL; Davila ML
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous targeting of Tim3 and A2a receptors modulates MSLN-CAR T cell antitumor function in a human cervical tumor xenograft model.
    Soltantoyeh T; Akbari B; Shahosseini Z; Mirzaei HR; Hadjati J
    Front Immunol; 2024; 15():1362904. PubMed ID: 38855110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Route of 41BB/41BBL Costimulation Determines Effector Function of B7-H3-CAR.CD28ζ T Cells.
    Nguyen P; Okeke E; Clay M; Haydar D; Justice J; O'Reilly C; Pruett-Miller S; Papizan J; Moore J; Zhou S; Throm R; Krenciute G; Gottschalk S; DeRenzo C
    Mol Ther Oncolytics; 2020 Sep; 18():202-214. PubMed ID: 32728609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hu8F4-CAR T cells with mutated Fc spacer segment improve target specificity and mediate anti-leukemia activity in vivo.
    He H; Vedia RA; Lu S; Li Q; Cox KR; St John L; Sergeeva A; Clise-Dwyer K; Alatrash G; Shpall EJ; Ma Q; Molldrem JJ
    Cytotherapy; 2024 Nov; 26(11):1331-1340. PubMed ID: 39033444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.
    Thokala R; Olivares S; Mi T; Maiti S; Deniger D; Huls H; Torikai H; Singh H; Champlin RE; Laskowski T; McNamara G; Cooper LJ
    PLoS One; 2016; 11(8):e0159477. PubMed ID: 27548616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Siglec-4 Derived Spacer Improves the Functionality of CAR T Cells Against Membrane-Proximal Epitopes.
    Schäfer D; Henze J; Pfeifer R; Schleicher A; Brauner J; Mockel-Tenbrinck N; Barth C; Gudert D; Al Rawashdeh W; Johnston ICD; Hardt O
    Front Immunol; 2020; 11():1704. PubMed ID: 32849600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers.
    Jin Y; Dunn C; Persiconi I; Sike A; Skorstad G; Beck C; Kyte JA
    Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.
    Cheng Z; Wei R; Ma Q; Shi L; He F; Shi Z; Jin T; Xie R; Wei B; Chen J; Fang H; Han X; Rohrs JA; Bryson P; Liu Y; Li QJ; Zhu B; Wang P
    Mol Ther; 2018 Apr; 26(4):976-985. PubMed ID: 29503204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis.
    Acharya S; Basar R; Daher M; Rafei H; Li P; Uprety N; Ensley E; Shanley M; Kumar B; Banerjee PP; Melo Garcia L; Lin P; Mohanty V; Kim KH; Jiang X; Pan Y; Li Y; Liu B; Nunez Cortes AK; Zhang C; Fathi M; Rezvan A; Montalvo MJ; Cha SL; Reyes-Silva F; Shrestha R; Guo X; Kundu K; Biederstädt A; Muniz-Feliciano L; Deyter GM; Kaplan M; Jiang XR; Liu E; Jain A; Roszik J; Fowlkes NW; Solis Soto LM; Raso MG; Khoury JD; Lin P; Vega F; Varadarajan N; Chen K; Marin D; Shpall EJ; Rezvani K
    Cancer Discov; 2024 Oct; 14(10):1879-1900. PubMed ID: 38900051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD8α Structural Domains Enhance GUCY2C CAR-T Cell Efficacy.
    Baybutt TR; Entezari AA; Caspi A; Staudt RE; Carlson RD; Waldman SA; Snook AE
    Cancer Biol Ther; 2024 Dec; 25(1):2398801. PubMed ID: 39315411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia.
    Sedloev D; Chen Q; Unglaub JM; Schanda N; Hao Y; Besiridou E; Neuber B; Schmitt A; Raffel S; Liu Y; Janssen M; Müller-Tidow C; Schmitt M; Sauer T
    J Hematol Oncol; 2024 Sep; 17(1):85. PubMed ID: 39285441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-1BB enhancement of CAR T function requires NF-κB and TRAFs.
    Li G; Boucher JC; Kotani H; Park K; Zhang Y; Shrestha B; Wang X; Guan L; Beatty N; Abate-Daga D; Davila ML
    JCI Insight; 2018 Sep; 3(18):. PubMed ID: 30232281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-TIM3 chimeric antigen receptor-natural killer cells preferentially target primitive acute myeloid leukemia cells with minimal fratricide and exhaustion.
    Klaihmon P; Samart P; Rojanasakul Y; Issaragrisil S; Luanpitpong S
    Exp Hematol Oncol; 2024 Jul; 13(1):67. PubMed ID: 38992654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.